CEACAM6
Basic information
Region (hg38): 19:41750977-41772211
Previous symbols: [ "NCA" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CEACAM6 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 22 | 25 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 22 | 2 | 2 |
Variants in CEACAM6
This is a list of pathogenic ClinVar variants found in the CEACAM6 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-41755651-T-C | not specified | Uncertain significance (May 24, 2024) | ||
19-41755684-A-G | not specified | Uncertain significance (Mar 29, 2022) | ||
19-41755688-A-T | not specified | Uncertain significance (Jan 31, 2024) | ||
19-41756657-C-T | not specified | Uncertain significance (Dec 16, 2023) | ||
19-41756789-G-A | Benign (Dec 28, 2017) | |||
19-41756810-G-T | not specified | Uncertain significance (Aug 30, 2021) | ||
19-41756842-C-A | not specified | Uncertain significance (Mar 04, 2024) | ||
19-41756842-C-T | not specified | Likely benign (Apr 13, 2022) | ||
19-41756852-C-T | not specified | Uncertain significance (Aug 17, 2022) | ||
19-41756869-G-A | not specified | Uncertain significance (Oct 04, 2022) | ||
19-41756906-T-C | not specified | Uncertain significance (Nov 05, 2021) | ||
19-41756923-G-C | not specified | Uncertain significance (May 05, 2023) | ||
19-41756936-C-T | not specified | Uncertain significance (Dec 21, 2022) | ||
19-41761249-C-T | not specified | Uncertain significance (Oct 29, 2021) | ||
19-41761253-G-C | not specified | Uncertain significance (Jun 07, 2023) | ||
19-41761311-G-A | not specified | Uncertain significance (Jan 20, 2023) | ||
19-41761359-T-A | not specified | Uncertain significance (Jun 18, 2021) | ||
19-41761399-A-T | not specified | Uncertain significance (Feb 15, 2023) | ||
19-41761437-G-A | not specified | Uncertain significance (Jul 26, 2022) | ||
19-41761449-G-A | not specified | Uncertain significance (Jun 18, 2021) | ||
19-41761473-A-G | not specified | Uncertain significance (Dec 16, 2023) | ||
19-41761486-C-T | not specified | Likely benign (Nov 29, 2023) | ||
19-41762013-C-T | not specified | Uncertain significance (Mar 01, 2023) | ||
19-41762045-C-T | Benign (Apr 16, 2018) | |||
19-41762068-A-T | not specified | Uncertain significance (Aug 02, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CEACAM6 | protein_coding | protein_coding | ENST00000199764 | 5 | 21229 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000119 | 0.596 | 125734 | 0 | 10 | 125744 | 0.0000398 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.188 | 198 | 191 | 1.04 | 0.0000108 | 2209 |
Missense in Polyphen | 50 | 59.007 | 0.84736 | 820 | ||
Synonymous | -1.07 | 92 | 79.9 | 1.15 | 0.00000496 | 725 |
Loss of Function | 0.949 | 11 | 15.0 | 0.735 | 8.13e-7 | 156 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000618 | 0.0000618 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000575 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000466 | 0.0000440 |
Middle Eastern | 0.0000575 | 0.0000544 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Cell surface glycoprotein that plays a role in cell adhesion and tumor progression (PubMed:2803308, PubMed:2022629, PubMed:1378450, PubMed:8776764, PubMed:11590190, PubMed:10910050, PubMed:14724575, PubMed:16204051). Intercellular adhesion occurs in a calcium- and fibronectin-independent manner (PubMed:2022629, PubMed:16204051). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (PubMed:2803308, PubMed:2022629, PubMed:8776764, PubMed:11590190, PubMed:16204051). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764). Plays a role in neutrophil adhesion to cytokine-activated endothelial cells (PubMed:1378450). Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion (PubMed:16204051). Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells (PubMed:10910050, PubMed:14724575). {ECO:0000269|PubMed:10910050, ECO:0000269|PubMed:11590190, ECO:0000269|PubMed:1378450, ECO:0000269|PubMed:14724575, ECO:0000269|PubMed:16204051, ECO:0000269|PubMed:2022629, ECO:0000269|PubMed:2803308, ECO:0000269|PubMed:8776764}.;
- Pathway
- Neutrophil degranulation;Extracellular matrix organization;Innate Immune System;Immune System;Fibronectin matrix formation;Cell surface interactions at the vascular wall;Hemostasis
(Consensus)
Recessive Scores
- pRec
- 0.0690
Intolerance Scores
- loftool
- 0.618
- rvis_EVS
- -0.05
- rvis_percentile_EVS
- 50.34
Haploinsufficiency Scores
- pHI
- 0.0412
- hipred
- N
- hipred_score
- 0.278
- ghis
- 0.403
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.252
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- apoptotic process;homophilic cell adhesion via plasma membrane adhesion molecules;heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules;signal transduction;positive regulation of cell population proliferation;positive regulation of cell migration;positive regulation of heterotypic cell-cell adhesion;neutrophil degranulation;leukocyte migration;positive regulation of endothelial cell-matrix adhesion via fibronectin;negative regulation of anoikis
- Cellular component
- extracellular space;plasma membrane;cell surface;apical plasma membrane;anchored component of membrane;azurophil granule membrane
- Molecular function
- protein binding;identical protein binding;protein heterodimerization activity